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Abstract Hyperammonemia is a life-threatening condition
which can affect patients at any age. Elevations of ammonia
in plasma indicate its increased production and/or decreased
detoxification. The hepatic urea cycle is the main pathway
to detoxify ammonia; it can be defective due to an inherited
enzyme deficiency or secondary to accumulated toxic
metabolites or substrate depletion. Clinical signs and
symptoms in hyperammonemia are unspecific but they are
mostly neurological. Thus, in any unexplained change in
consciousness or in any unexplained encephalopathy,
hyperammonemia must be excluded as fast as possible.
Any delay in recognition and start of treatment of hyper-
ammonemia may have deleterious consequences for the
patient. Treatment largely depends on the underlying cause
but is, at least in pediatric patients, mainly aimed at
establishing anabolism to avoid endogenous protein break-
down and amino acid imbalances. In addition, pharmaco-
logical treatment options exist to improve urea cycle
function or to remove nitrogen, but their use depend on
the underlying disorder. To improve the prognosis of acute
hyperammonemia, an increased awareness of this condition
is probably more needed than anything else. Likewise, the
immediate start of appropriate therapy is of utmost
importance. This review focuses on a better understanding
of factors leading to ammonia elevations and on practical
aspects related to diagnosis and treatment in order to
improve clinical management of hyperammonemia.
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Introduction
Hyperammonemic disorders not due to general liver failure
are rare and the symptoms non-specific. The clinical
presentation varies depending on age of the patient and on
type and severity of the underlying disorder. In all age
groups, loss of appetite and then vomiting are early and
reversible findings if treated. In newborns, first symptoms
are poor feeding, vomiting, seizures, unstable body tem-
perature, respiratory distress or poor peripheral blood
circulation leading to an initial suspicion of intracranial
bleeding, septicemia or meningitis; in infants, vomiting
may evoke pyloric stenosis, cow milk intolerance or
infectious enteritis; in children, adolescents and adults,
vomiting, ataxia, confusion, disorientation, hallucinations
or abnormal behavior point to central nervous system or
psychiatric disorders. In all age groups, the change of
consciousness should shift the search to intoxications,
encephalitis or metabolic disorders. Since more common
disorders are considered first, valuable time is often lost
when hyperammonemia has already reached levels above
400–500 μmol/L thus increasing the risk of irreversible
brain damage, of neurodevelopmental retardation or even
death.
The first goal of this review is to stimulate the reader to
consider the rare metabolic disorders in presence of non-
specific symptoms in order to rule out hyperammonemia
and—if present—to prevent irreversible damage to the
brain by timely action. The second goal is to outline the
principles of the available treatments and necessary controls
in order to empower the pediatrician to follow and guide
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the patient when the disorder has been diagnosed. An
increased awareness of all medical professionals towards
the possibility of hyperammonemia is needed for an
improved prognosis of affected patients.
Background
Physiology
About 90% of nitrogen-containing compounds are normally
excreted as urea. They originate from the obligate oxidation
of amino acids and from excess waste nitrogen, mainly
from amino acids not used for protein neo-synthesis, from
cell turnover of hydrolyzed body protein and from protein
intake. The bulk of protein mass is in the skeletal and
visceral musculature. The rate of protein breakdown is
relatively constant while the synthesis is regulated e.g. by
hormones, cytokines and available substrates. The capacity
of urea formation adapts normally within a few days to
changes of the amount of protein intake.
Ammonia (NH3) is a constituent of all human body
fluids and at neutral pH present mostly (>98%) in its
ionized form, ammonium (NH4
+) [8]. This is physiologi-
cally advantageous because ammonium, in comparison to
ammonia, barely permeates cell membranes. Mainly for
convention, “ammonia” is used in this review although
“ammonium” would be the correct biochemical term. The
concentration of ammonia in human plasma is micromolar
and varies in venous, arterial or capillary blood as well as
depending on the time and mode of sampling (see below).
Tissue ammonia concentrations are higher and ammonia is
trapped as ammonium in compartments with lower pH such
as in lysosomes and renal tubules [3]. Plasma ammonia
concentrations depend on the age of the patient and assay
method used but it should be noted that well-defined
reference limits for ammonia do not exist (limits for use in
clinical practice are depicted in Table 1 [18]).
Hyperammonemia indicates an elevation of ammonia in
blood and tissues by its increased production and/or
decreased detoxification and is a strong indicator of
abnormal nitrogen homeostasis. Since in clinical practice
ammonia can be determined very fast but also because of
the associated neurotoxicity, ammonia belongs to the core
parameters of metabolic medicine together with blood
gases, glucose, lactate and ketone bodies. However, the
clinical condition of a patient should guide the management
rather than solely ammonia concentrations because they can
be fluctuating and may not entirely correlate with already
impaired brain function.
In mammals, skeletal muscle and intestinal mucosa are
mainly responsible for ammonia production (Fig. 1a).
Many of the reactions of amino acid metabolism take place
in skeletal muscle, where protein is broken down and where
single amino acids are transaminated for new protein
synthesis or to form glutamine from glutamate and/or
alanine from pyruvate [28]. Glutamine is not only the most
abundant amino acid in the human organism, the temporary
storage form of waste nitrogen and the main transport form
of amino groups between organs but also a major source of
ammonia if deaminated by glutaminase [48]. Also in
skeletal muscle, deamination of adenosine monophosphate,
particularly during physical exercise, results in ammonia
production. In intestinal mucosa, ammonia is produced after
uptake of amino acids as a result of glutamine deamination.
In colon and bladder, microorganisms expressing enzymes
enabling protein and urea degradation, respectively, can
lead to hyperammonemia [40, 41, 66, 67]. About 25% of
endogenous ammonia is derived from intestinal production
[46, 63].
For the final transformation of glutamine/glutamate to
ammonia and for detoxification of the portal ammonia and
export of ammonia, the liver and to a certain extent the kidney
play the central role. In liver, the urea cycle is located in
periportal hepatocytes and provides a high capacity for
detoxification of the vast amount of surplus nitrogen while
glutamine synthetase, expressed only in perivenous hepato-
cytes, serves as back-up system with high affinity (but low
capacity) to ammonia (Fig. 1b) [36]. Accordingly, hyper-
ammonemia can occur in many acquired and inherited
hepatic disorders. In kidney, ammonia is formed from
glutamine deamination. However, renal ammonia production
mainly contributes to buffering H+ ions while excretion of
ammonia in urine plays only a minor role in overall
ammonia detoxification (Fig. 1a and b show the key players
of ammonia production and detoxification).
Practical points
➢ Ammonia is neurotoxic itself and indicates increased ammonia
production or decreased ammonia detoxification
➢ Ammonia determination is crucial for many metabolic disorders
➢ The neurological condition of the patient should guide the clinical
management rather than ammonia levels alone
Table 1 Plasma ammonia concentrations depending on age of
patients (adapted from [18])
μmol/l μg/dl
Newborns (arterial cord blood) 50–159 85–271
Infants and children 24–48 41–82
Adults (female) 11–48 19–82
Adults (male) 15–55 26–94
Conversion μg/dl×0.5872=μmol/l. The levels given are decision
limits which should be interpreted together with the clinical situation
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Neurotoxicity of ammonia
The brain is the main organ affected by hyperammonemia
[21]. Ammonia enters the brain mainly by diffusion, but it
is to a lesser extent also produced by brain metabolism [47].
A number of reversible and irreversible metabolic and
neurotransmitter disturbances and ensuing morphologic
changes add up to severe brain toxicity but the exact
pathogenic mechanisms still need to be unraveled [4, 15,
29, 31]. Depending on age as well as duration and level of
hyperammonemia severe cerebral edema, brain stem herni-
ation and death can result. In acute hyperammonemia,
astrocytes are swollen as observed by microscopy. One
important factor in this pathology is the osmotic effect of
newly synthesized brain glutamine on astrocytes which is
taken up together with water [13, 69] but many other
Fig. 1 a, b. Illustration of the
key players of ammonia pro-
duction and detoxification. a
Simplified graph showing the
interplay of intestine and skele-
tal muscle (organs that produce
ammonia and glutamine) with
liver and kidney (organs that
detoxify ammonia). Ammonia is
detoxified in liver while gluta-
mine is not. b This simplified
graph focuses on periportal and
perivenous hepatocytes as the
two ammonia detoxifying com-
partments in liver. Ammonia is
metabolized with high capacity
but low affinity in the urea cycle
which is solely expressed in
periportal hepatocytes. As
back-up, ammonia is detoxified
by the action of glutamine syn-
thetase that is solely expressed
in perivenous hepatocytes and
has a low capacity but high
affinity towards ammonia. Urea
and glutamine re-enter the cir-
culation to be excreted in urine
or further metabolized in the
kidney, respectively. Urea cycle
enzymes abbreviated: NAGS N-
acetylglutamate synthase, CPS1
carbamoylphosphate synthetase
1, OTC ornithine transcarbamy-
lase, ASS argininosuccinate syn-
thetase, ASL argininosuccinate
lyase, ARG1 arginase 1
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mechanisms contributing to brain toxicity of ammonia have
been suggested and the reader is referred to recent reviews
[4, 10, 11, 14, 44, 62].
Metabolic crisis
Metabolic crises occur whenever the load of waste nitrogen
exceeds the detoxification capacity. In the periportal liver
(and to a lesser extent in the intestinal mucosa), the main
part of ammonia from the gut is handled by urea synthesis
[36]. All enzymes and membrane transporters needed are
expressed in these cell systems [17, 48, 51]. In all other
organs and cell systems including perivenous hepatocytes,
amino groups and ammonia are detoxified by glutamine
formation [37].
If the capacity for detoxification of ammonia is
insufficient a vicious cycle can lead to crises. This occurs
when the increasing systemic ammonia leads to loss of
appetite and vomiting. Rapid intervention is needed to
avoid a further increase of ammonia, i.e. when protein
synthesis is reduced and catabolism prevails like during
postpartum physiologic weight loss in neonates, infections
(even minor ones) or increase of nutritional protein supply
beyond the actual needs.
Therapeutic measures are initially non-specific in order
to reduce hyperammonemia below 400–500 μmol/L or
optimally prevent its rise to such levels; a rapid diagnosis
should be reached to allow the application of more efficient
measures [6, 43]. Otherwise, the risk of irreversible damage
to the brain is high.
Biochemical basis of primary hyperammonemia
In the mammalian organism, the major part of ammonia is
detoxified by the urea cycle (Figs. 1a, b and 2). This cycle
is fully expressed only in liver and intestinal mucosa and
comprises six enzymatic steps of which three are intra-
mitochondrial and three cytosolic [36]. The urea cycle has a
second role—the synthesis of arginine—which is important
for the treatment of hyperammonemia [12].
A defect in one of the six urea cycle enzymes and two
membrane transporters results in so called primary hyper-
ammonemia, while metabolic defects outside the urea cycle
as well as side effects of drugs can lead to secondary
hyperammonemia. This classification is by no means purely
academic but is part of any differential diagnosis of
unexplained hyperammonemia (Table 3).
The single most important of the urea cycle disorders
(UCDs) is ornithine transcarbamylase (OTC) deficiency
because it is the most common one and the only X-linked
[57]. While male patients are often affected by severe
neonatal metabolic decompensation, females with OTC
Fig. 2 Influence of metabolic disorders on function of urea cycle
leading to secondary hyperammonemia. Figure showing sites of action
of various compounds on urea cycle function by either leading to
inhibition of enzymes (NAGS or CPS1) or to a decrease in
intermediate substrates (both negative actions are depicted as - ).
HIHA hyperinsulinism-hyperammonemia syndrome, FAOD fatty acid
oxidation defects, PDHCD pyruvate dehydrogenase complex disor-
ders , OA organic acidemias, HHH hyperorni thinemia-
hyperammonemia-homocitrullinuria syndrome, PC pyruvate carbox-
ylase defect, Citrin Citrullinemia type 2, LPI lysinuric protein
intolerance, P5CS pyrroline-5-carboxylate synthetase defect. The site
of action of valproate has also been added. + depicts the stimulatory
effect of NAG on CPS1. Figure adapted from [53]
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deficiency can present with a broad clinical picture [57, 59].
Depending on random X-inactivation, the resulting OTC
phenotype is a continuum and affected females may remain
asymptomatic but may also resemble hemizygous males
[50]. All other UCDs are autosomal recessively inherited.
Biochemical basis of secondary hyperammonemia
Many inborn errors of metabolism result in accumulation of
toxic products which can lead to inhibition of other
metabolic pathways (Fig. 2). This is also the case for the
urea cycle which can loose its ammonia detoxifying
capacity because accumulating metabolites can impair the
synthesis of N-acetylglutamate (NAG), the obligate activa-
tor of CPS1. Furthermore, some organic acids (e.g.
methylcitrate in case of propionic acidemia or methylma-
lonic acidemia) inhibit the mitochondrial Krebs cycle and
thus the availability of α-ketoglutarate as ammonia accep-
tor for glutamate synthesis. In addition, deficiency of
acetyl-CoA or glutamate in the mitochondria or of
substrates required for normal urea cycle function can lead
to secondary hyperammonemia (see also Table 3).
Increased ammonia production caused by bacterial
overgrowth can occur in bladders, uretero-sigmoid shunts
or within the intestine. This can be seen in intestinal
hypomotility of any cause, e.g. postoperative, in diabetic
gastroparesis or myotonic muscular dystrophy. Besides,
hyperammonemia can result if ammonia does not reach the
detoxifying hepatocytes, e.g. in open Ductus venosus or
portocaval shunting, and this might also contribute to the
unclear phenomenon of “transient hyperammonemia of the
newborn” (THAN). In addition, drugs can lead to hyper-
ammonemia which was mostly reported secondary to
valproate but other antiepileptic agents, L-asparaginase,
furosemide and salicylic acid are also possible triggers of
severe ammonia elevations [4, 7, 35].
Key points
➢ Primary hyperammonemia results from a defect of one of the urea
cycle enzymes or transporters of ornithine or aspartate/glutamate
➢ Secondary hyperammonemia is caused by a defect outside the urea
cycle that indirectly affects urea cycle function via inhibition or
substrate deficiency
Clinical signs and symptoms
General aspects of signs and symptoms
of hyperammonemia
Since ammonia is toxic mainly to the brain, most signs and
symptoms of hyperammonemia are neurological. This is
even true for “vomiting” as one of the most common signs
of hyperammonemia at all ages which is not a pure
abdominal sign but also a neurological sign.
Although non-specific at all ages, the clinical presen-
tation will now be discussed in relation to certain age
groups.
Signs and symptoms in neonates
Neonates have long been regarded as the group of patients
most affected by hyperammonemia. This is not true with
regard to the proportion of patients beyond the neonatal
period but still partly true in clinical practice. In primary
and secondary defects of the urea cycle, the pregnancy and
first days of life will be uneventful because the maternal
urea cycle will clear off any surplus nitrogen from the fetus.
Depending on the specific defect, postnatal catabolism can
lead to a clinically relevant ammonia increase within days.
In severe primary defects of the urea cycle, e.g. if the
intramitochondrial enzymes are defective, the asymptomat-
ic interval may be as short as 24 h. Milder variants might
only decompensate during severe states of catabolism in
later life. Up to 50% of urea cycle patients present with
respiratory alkalosis. Since septicemia is the most common
differential diagnosis in a sick neonate and is in general
accompanied by metabolic acidosis, presence of respiratory
alkalosis should alert the clinician to perform an immediate
re-evaluation including ammonia determinations. Con-
firmed septicemia does not exclude a primary hyper-
ammonemic defect, since the catabolism associated with
infection can provoke the manifestation of the genetic
defect.
Signs and symptoms in infants and young children
Despite an uneventful postnatal period, affected infants
and young children can manifest during any catabolic
state. Especially in late infancy, protein anabolism is
decreasing when postnatal growth slows down. This can
be estimated from levels of urea production which are
very low during rapid growth but increase after late
infancy [13]. Any imbalance in energy demands, e.g.
during febrile illness when nutritional intake is decreased,
will result in endogenous protein catabolism and risk for
hyperammonemia.
Signs and symptoms in older children and adults
Hyperammonemia can manifest for the first time at any age.
Even an uneventful history with many catabolic situations but
no signs of metabolic decompensation must not be interpreted
as an exclusion of a primary or secondary urea cycle
dysfunction. A very early in life self-chosen vegetarian diet
Eur J Pediatr (2011) 170:21–34 25
is a striking finding in many patients with hyperammonemia.
Along this, in any unexplained neurological symptoms and
especially in any unexplained encephalopathy hyperammo-
nemia should be excluded at the very beginning of the
diagnostic evaluation.
Practical points
➢ Determine plasma ammonia in all neonates with suspected
septicemia
➢ Be alert if respiratory alkalosis is present in neonatal septicemia
➢ Take a good history including information regarding a self-chosen
vegetarian diet
➢ Be alert if loss of appetite or vomiting are accompanied by change
in consciousness
➢ Exclude hyperammonemia in every unexplained encephalopathy
➢ Exclude hyperammonemia in every unexplained change in
consciousness
Signs and symptoms of acute and chronic hyperammo-
nemia are, irrespective of the age of the patient, summa-
rized in Table 2.
Differential diagnosis
The list of differential diagnoses of hyperammonemic
disorders is long. The most important disorders can be
grouped as listed in Table 3 and as shown in Fig. 2.
Laboratory work-up
The goal is to suspect and to rule in or out hyper-
ammonemia without delay. If hyperammonemia is con-
firmed, other laboratory investigations should be done
including blood gases, glucose, creatinine, electrolytes,
plasma acylcarnitines and amino acids, coagulation factors,
albumin, pre-albumin, AST, ALT, CRP, as well as spot
urine analysis for organic acids and orotic acid. For reliable
results the blood should ideally be taken from a central
vessel, especially in patients with poor peripheral circula-
tion or after seizures (see below). In a comatose patient,
preservation of EDTA-blood for later DNA analysis is
recommended. The list of investigations should be estab-
lished together with the specialized center to which hyper-
ammonemic patients will be sent. All samples collected
should be transferred together with the patient to the
metabolic center taking in charge the confirmation of
diagnosis and treatment of the patient. Valuable time can
be gained by such a procedure.
How to diagnose hyperammonemia?
In the emergency situation, blood should be drawn at once for
a rapid ammonia determination but the following preanalyt-
ical aspects should still be taken into consideration [8, 23]:
■ Measurement of ammonia requires free flowing
venous or arterial blood while capillary blood is only
useful for excluding hyperammonemia [3].
■ Except in emergency situations, sampling should be
done in fasting state or at least 4–6 h after a meal.
■ Struggling of the child or physical exercise before
the blood is taken can lead to false high ammonia
concentrations.
■ To prevent false high ammonia levels secondary to
hemolysis blood must be collected with the use of an
anticoagulant (EDTA or heparin) and preferably in a
chilled tube.
■ It has become practice in many hospitals to keep the
sample on ice directly after blood is drawn. However, it
should be noted that even short-time storage on ice can
Acute hyperammonemia Chronic hyperammonemia
Lethargy Protein aversion and self-chosen vegetarian diet
Somnolence Headaches and migraine
Coma Tremor, ataxia, dysarthria, and asterixis
Vomiting (metabolic alkalosis) Confusion, lethargy, and dizziness
Seizures Hyperactive, aggressive, or self-injurious behavior
Peripheral circulatory failure (metabolic acidosis) Cognitive deficits and learning disabilities
Cerebral edema (respiratory alkalosis) Abdominal pain and vomiting
Liver failure Failure to thrive
Multiorgan failure Elevated liver enzymes
Post-partum psychosis Seizures
In neonates, sepsis-like picture Psychiatric symptoms
In neonates, respiratory distress Stroke-like episodes
In neonates, hypo/hyperthermia Episodic character of signs and symptoms
Table 2 Signs and symptoms
of acute and chronic
hyperammonemia
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lead to partial freezing resulting in hemolysis; there-
fore, ice-water should be used instead.
■ Plasma should be separated as soon as possible but
certainly within 15–30 min.
Practical points
➢ Get an immediate ammonia analysis if hyperammonemia is
suspected
➢ Obtain free flowing blood
➢ Use capillary blood only for exclusion of hyperammonemia
➢ Separate plasma within 15–30 min
➢ Use ice-water for transport of the sample instead of storage on ice
Laboratory tests
There are different analytical methods of ammonia
determination including titration, colorimetric/fluorimet-
ric, electrode-based and enzymatic methods [8]. It should
be noted that the normal values given by the manufac-
turers of some methods are unfortunately sometimes
inaccurate. In clinical practice, a widely used method
utilizing glutamate dehydrogenase (GLDH) determines
ammonia concentrations by analyzing the decrease in
absorption at 340 nm caused by oxidation of NADPH as
shown in the following equation: α-ketoglutarate þ
NH3 þ NADPH!GLDH glutamateþ NADPþ.
Bedside tests
The major advantage of bedside ammonia determination is
to get a rapid result and thus fast information on nitrogen
homeostasis. If bedside tests are done correctly, i.e. from
free flowing blood drops (no massage or squeezing of heels
and fingertips) in warm heels or fingers picked in non-
traumatized tissue, the result will be probably reliable and
available within 3 min. However, the result will only allow
to exclude hyperammonemia.
Table 3 Differential diagnosis of hyperammonemic disorders
Primary hyperammonemia caused by defects of urea cycle enzymes or transporters
■ N-acetylglutamate synthase deficiency
■ Carbamoylphosphate synthetase 1 deficiency
■ Ornithine transcarbamylase deficiency
■ Argininosuccinate synthetase deficiency
■ Argininosuccinate lyase deficiency
■ Arginase 1 deficiency
■ Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome leading to intramitochondrial ornithine deficiency
■ Citrin deficiency (citrullinemia type 2) leading to aspartate deficiency
Secondary hyperammonemia caused by inhibition of the urea cycle
■ Propionic acidemia leading to glutamate deficiency
■ Methylmalonic acidemias leading to production of methylcitrate
■ 3-Hydroxy-3-methylglutaryl-CoA-lyase deficiency
■ ATP deficiency of any cause leading to secondary CPS1 deficiency
■ Valproate
Secondary hyperammonemia caused by deficiency of substrates
■ Fatty acid oxidation defects leading to CoA deficiency
■ Carnitine cycle disorders leading to CoA deficiency
■ Pyruvate dehydrogenase complex disorders leading to CoA deficiency
■ Acute or chronic liver failure leading to CoA deficiency
■ Lysinuric protein intolerance leading to citrulline, arginine, and ornithine deficiency
■ Hyperinsulinism-hyperammonemia syndrome leading to glutamate deficiency
■ Pyruvate carboxylase deficiency leading to aspartate deficiency
■ Pyrroline-5-carboxylate synthetase deficiency leading to citrulline, arginine, and ornithine deficiency
Liver bypass
■ Open ductus venosus
■ Vascular malformations resulting in portocaval shunting
Unclear
■ Transient hyperammonemia of the newborn
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In addition, there are some concerns towards the use of
ammonia bedside tests especially outside the hospital: one
is related to the fact that due to contamination by
intracellular fluid, capillary blood ammonia levels might
be elevated. Another problem is the limited capability to
precisely measure high ammonia levels (the upper limit of
ammonia bedside tests is often below 300 μmol/L) [24]
which might lead to underestimation and thus a dangerous
delay. Furthermore, ammonia measurements at home can,
opposite to their intention, lead to increased stress within
the family caused by repetitive analyses. However, if used
in a hospital setting, ammonia bedside tests can speed up
the time to diagnosis in emergency situations both of
known and not yet known patients.
Outlook: continuous monitoring of ammonia
Analyzing ammonia continuously instead of only a few
times a day would allow for better understanding of
fluctuating levels and closer regulation of therapies but this
is not yet feasible. Recently, measurement of human breath
ammonia using a liquid-film conductivity sensor was
reported [56], but it remains to be seen whether this or
yet another method for continuous monitoring will come
into clinical practice.
What to do with slightly raised plasma ammonia
concentrations?
If plasma ammonia is only slightly raised, it might be
difficult to decide how to proceed. Considering the
preanalytical pitfalls of ammonia determination, slight
increases of ammonia might well be artificial. The
following approach might be helpful in clinical practice:
■ Repeat the plasma ammonia immediately.
■ Find out the conditions under which the blood was
collected, in particular, was the sample obtained after a
meal and was the child struggling?
■ Find out the conditions the sample was handled, in
particular, how long was the time to analysis and
storage?
■ Review the clinical and family history very carefully.
In particular, is there any evidence of previous episodes
of encephalopathy—mild or severe?
Amino acids
Ammonia levels cannot replace close observation of plasma
amino acid profiles including their careful interpretation [60].
Therefore, in any patient with hyperammonemia amino acid
profiles are necessary not only for differential diagnosis in
newly diagnosed patients but also for optimal treatment.
Thus, amino acids must be controlled and interpreted during
the emergency phase at least daily and later in the course less
frequently but at least every 3 months.
Of utmost importance is the concentration of glutamine
which is less fluctuating than ammonia and most other
amino acids and plays a central role in hyperammonemic
neurotoxicity [1, 22]. The major part of glutamine in the
CNS is newly synthesized within the brain while the
transport system at the blood–brain barrier has an only
low affinity for glutamine. At the same time, transamina-
tions by glutaminase in endothelial cells [68] can diminish
differences of arterio-venous glutamine concentrations even
in presence of experimental hepatic coma. Thus, increased
plasma glutamine levels are an indicator of the increased
nitrogen load of the organism but are by no means a
predictor or even precursor of brain glutamine.
In addition, essential amino acids need to be closely
monitored with special emphasis on branched chain amino
acids (BCAA) [3, 54, 55, 58]. These are a major nitrogen
source for endogenous glutamine synthesis and might
become depleted in hyperglutaminemia. Also, the nitrogen
scavenger drug phenylacetate is known to aggravate BCAA
deficiency because nitrogen molecules lost by excretion of
phenylacetylglutamine originate in relevant amounts from
BCAA [55].
Neuroimaging
To estimate the effect of acute or chronic ammonia on the
brain, neuroimaging can provide additional information.
Unfortunately, widely available techniques such as ultrasound
(by scanning through the open fontanel in neonates and young
infants) and computed tomography cannot detect acute or
moderate changes of brain morphology except very severe
brain edema. Color duplex sonography might help to detect
brain edema but there are no studies on the sensitivity of this
method in hyperammonemia. However, the role of neuro-
imaging in management of hyperammonemia has been
evolving in recent years mainly using functional magnetic
resonance imaging (fMRI), diffusion tensor imaging (DTI)
and 1H/13C magnetic resonance spectroscopy (MRS) [33].
While ammonia cannot be followed directly by MRS,
hyperammonemia leads to a number of secondary changes.
One is the change in glutamine and myoinositol levels
detected by MRS [20, 33]. Studies have shown that both
acute and chronic hyperammonemia result in an increase of
glutamine and at the same time in a decrease in myoinositol
which functions as a compensatory organic osmolyte in
astrocytes [32, 33, 69].
Although the role of neuroimaging needs further
evaluation, it will hopefully become an important tool
mainly to define the effect of subclinical hyperammonemic
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episodes and of chronic moderate hyperammonemia and
hyperglutaminemia on the brain.
Management of hyperammonemic crisis
Management of hyperammonemic crises is beyond the
resources of non-specialized hospitals and transfer to a
metabolic center is needed to allow efficient interventions.
How to proceed if hyperammonemia is suspected?
The result of plasma ammonia should be available within
30-(60) min at all times. Meanwhile, protein supply should
be stopped and glucose supplied (see below and Fig. 3).
Any somnolent or pre-comatose patient suspected to be
hyperammonemic should be transferred to a specialized
center without delay, together with urine and plasma
samples (kept on ice or frozen) and this will allow to gain
time. The center should have the resources for ruling out or
establishing the diagnosis within 12 h and for starting the
specific therapy of a metabolic crisis.
Practical points
➢ Actively seek the result of plasma ammonia within 30–(60) min
➢ Stop protein supply
➢ Start glucose infusion±insulin (control blood lactate after 2 h)
➢ Contact metabolic center for advice on management
➢ Transfer any somnolent or pre-comatose patient (together with
urine and plasma samples for further analyses) to the experienced
center
Fig. 3 Algorithm for the management of hyperammonemia in a
newly recognized patient. Algorithm for the management of hyper-
ammonemia in a newly recognized patient and for interpretation of
first laboratory results. The ammonia limits given are decision limits
which should guide the next steps. With this algorithm, most of the
differential diagnoses listed in Table 3 can be detected. Citrin
deficiency (where high citrulline and arginine in plasma can be
found) was not included in this figure because it is extremely rare
outside Japan. P plasma, U urine, B blood, N normal, D behind the
enzyme abbreviations stands for deficiency, ASA argininosuccinic acid
(specific metabolite of ASLD). Asterisk Orotic acid in urine might
initially be low or only slightly elevated in a male OTC newborn
(personal communications, M. Lindner, T. Marquardt, B. Fowler)
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How to proceed if hyperammonemia is confirmed?
Hyperammonemia is always an emergency situation.
Treatment should start immediately after elevated plasma
ammonia has been found and before any specific diagnosis
is made (see also Fig. 3). Since hyperammonemia is the
result of protein catabolism, this must be reversed as fast as
possible. Exogenous protein should be stopped for 24–48 h
but exogenous nitrogen sources make up for only a small
proportion of surplus nitrogen if endogenous protein
catabolism is ongoing. Thus, it is the combination of
stopping exogenous protein, reversing endogenous protein
catabolism by high doses of parenteral glucose sometimes
requiring additional insulin and the use of detoxifying drugs
that need to be initiated as fast as possible [13, 27]. If
hyperammonemia exceeds levels 300–400 μmol/L hemo-
diafiltration as the preferred method or, if not available,
hemodialysis or hemofiltration must be prepared rapidly [6,
43]. The detailed approach to this depends on the local
conditions but, as mentioned above, patients with a
metabolic crisis should always be treated in specialized
centers. See also Table 4.
Management of primary hyperammonemia
Until the diagnosis is available (ideally within 12–18 h after
detection of ammonia >200 μmol/L), stop of protein supply
and continuous infusion of high dose parenteral glucose (in
newborns at least 8–10 mg/kg/min) is maintained [6]. A
tentative treatment with carbamylglutamate has recently
been proposed in order to lower ammonia in known
propionic and methylmalonic acidemia, known NAGS
deficiency or even any unknown neonatal hyperammone-
mia [34, 61].
In primary UCDs, specific conservative treatment
options comprise the use of urea cycle metabolites distal
to the metabolic block. If hyperargininemia is excluded,
L-arginine HCl (initially intravenously) is the substance
most often used but citrulline can also be given in the
mitochondrial UCDs. Use of L-arginine aims at restoring
residual function of the urea cycle allowing for urinary
excretion of nitrogen as intermediate urea cycle metabo-
lites (citrulline or argininosuccinate) but also at avoiding
arginine deficiency [13, 43].
In addition, nitrogen scavenger drugs have a large
impact on treatment of hyperammonemia [9, 13, 26]. In
Europe, there are only two substances available, one of
which is a licensed drug (sodium phenylbutyrate) and the
other a chemical agent (sodium benzoate). For acute
intervention, sodium benzoate with or without sodium
phenylacetate (which is the active metabolite of sodium
phenylbutyrate) can be administered intravenously. Care
should be taken to avoid intoxication by excessive dosage
in newborns since their drug metabolizing enzymes need
4–5 days induction (Bachmann C, personal communica-
tion). Phenylacetate binds glutamine to form phenyl-
acetylglutamine while benzoate binds glycine to form
hippurate which are both excreted in urine. Both
conjugations take place in liver and require the presence
of coenzymeA (CoA). At start of treatment, a loading
dose of L-arginine as well as of nitrogen scavenger drug(s)
is given intravenously over 2 h followed by a maintenance
continuous infusion (see Table 4). Repetition of loading
doses is not recommended because of benzoate or phenyl-
butyrate toxicity [13]. If nitrogen scavengers are used,
plasma amino acids need to be controlled daily. The
benzoate dose must be reduced if glycine is below
100 μmol/L. If phenylacetylglutamine excretion is en-
hanced, leucine and isoleucine might become deficient
within days resulting in ongoing catabolism and limitation
of protein neo-synthesis unless they are substituted.
Energy should be provided as glucose and lipids
covering 110% of the energy demand. Enteral feeding
should be started as soon as possible on the basis of a low
protein diet [25, 42]. Breast milk can be given in limited
amounts (up to about 0.7 g protein/kg body weight/d) but
Table 4 Management of acute hyperammonemia
■ Stop oral protein intake and intravenous amino acid infusions
■ Provide high-energy intake, either oral as 10–25% glucose polymer or intravenous as glucose 8–10 mg/kg b.w./min (dose for neonates/small
infants) plus, in case of hyperglycemia, insulin
■ Transfer the patient to specialized center together with plasma and urine spot samples
■ Give intravenous L-arginine-HCl 2 mmol/kg b.w. as loading dose in 2 h, then 2 mmol/kg b.w. as continuous infusion in 24 h
■ Consider nitrogen scavengers (should not be given in secondary hyperammonemias): sodium benzoate 250–350 mg/kg b.w. as loading dose in
2 h, then 250–350 mg/kg b.w. as continuous infusion in 24 h, and/or sodium phenylacetate 250–350 mg/kg b.w. as loading dose in 2 h, then
250–350 mg/kg b.w. as continuous infusion in 24 h
■ Consider use of carbamylglutamate 200 mg/kg b.w. divided in three oral doses
■ Plan hemodiafiltration if initial ammonia is >500 μmol/L or if ammonia does not fall within 2 h after start of treatment
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the protein tolerance depends on the severity of the defect
and is highly variable between patients [43]. To treat and
prevent deficiencies of essential amino acids (EAAs),
special mixtures of EAAs which should be high in
branched chain amino acids [54] and low in neurotransmit-
ter precursors are given (as intravenous solution, e.g.
Aminosteril Hepa®, Fresenius; as enteral feed, e.g.
UCD®, Milupa or EAM®, SHS) [3]. The diet must be
adapted daily during the first weeks of treatment. Hidden
sources of protein supply such as blood or plasma
transfusions should be avoided or taken into account.
It should be noted, that excessive restriction of protein
supply and the ensuing amino acid imbalance and BCAA
deficiencies can cause ongoing catabolism resulting in
chronic moderate hyperammonemia.
Besides, other treatment modalities are currently dis-
cussed including L-ornithine-L-aspartate to increase protein
synthesis in skeletal muscle [39], hypothermia to decrease
energy demands in brain [64], N-methyl-D-aspartate recep-
tor antagonists to reduce glutamate toxicity [45] and others
but these are not yet proven concepts.
Practical points
➢ Provide at least 110% of daily energy demand, either oral or
intravenous
➢ Use L-arginine to restore urea cycle function
➢ Use nitrogen scavengers, but don’t use repeated loading doses
➢ Consider use of carbamylglutamate
➢ Start enteral feeding as soon as possible based on a low protein diet
➢ Consider supplementation of nutrients (EAAs, vitamins, minerals,
trace elements)
Treatment of secondary hyperammonemia
If hyperammonemia is secondary to inborn errors of
metabolism other than UCDs, it can still be life
threatening to the same extent as in primary hyper-
ammonemia. Nevertheless, treatment is based on rever-
sion of endogenous protein catabolism but is otherwise
focused on the underlying disorder. In organic acidemias
(including the iatrogenic hyperammonemia of valproate
treatment) drugs used for increasing waste nitrogen
excretion in UCDs are critical because they might result
in toxic drug accumulation due to intramitochondrial
CoA depletion. Likewise, amino acid mixtures high in
BCAA should not be given. If bacterial overgrowth in
intestine is considered to cause or contribute to hyper-
ammonemia, eradication of urease producing bacteria
with non-absorbable antibiotics (metronidazole, neomy-
cin) should be aimed for. Also, acidification of the
intestine with lactulose to shift NH3 to NH4
+ can
contribute to decreased ammonia uptake [2, 19].
Practical points
➢ Define and treat the underlying disorder
➢ Provide at least 110% of daily energy demand, either oral or
intravenous
➢ Be cautious with the use of nitrogen scavenger drugs in secondary
hyperammonemia
➢ Treat and prevent intestinal bacterial overgrowth by non-absorbable
antibiotics
➢ Consider acidification of intestinal tract with lactulose
Prognosis of hyperammonemia
For primary UCDs, the prognosis depends not only on the
genotype but on many endogenous and exogenous factors.
Patients without any residual enzyme activity generally
have a poor prognosis and often die in the first few days of
life. On the other extreme, females with OTC deficiency
with a favorable mosaicism and high levels of residual in
vitro activity usually have a good prognosis.
External causes like mild viral or bacterial infections
with sudden predominant catabolism or events leading to
prolonged vomiting can lead to excessive breakdown of
proteins and hence to hyperammonemia. In addition, severe
liver disease, trauma, extensive surgical interventions,
excessive protein intake or the post-partum period can lead
to the first metabolic decompensation well into adulthood.
Still, the consequences can be lethal. Since these events
cannot be predicted, any prognostic statement for an
individual patient is almost impossible and survival
statistics are of limited help.
Acute episodes
Acute episodes of hyperammonemia are always life
threatening [26]. A retrospective study analyzing the
outcome of neonatal onset UCDs showed that ammonia
levels at presentation above 300 μmol/L carry a high risk of
death or severe neurological sequelae and peak levels above
480 μmol/L at first hospitalization were never associated
with normal outcome [5]. Although these data are histor-
ical, first manifestations of acute hyperammonemia carry a
serious prognosis at all ages and unknown patients are at
risk because any delay in start of treatment contributes to
the poor outcome [65]. A recent cohort study revealed an
up to 45% mortality of boys with late-onset OTC
deficiency at the time of diagnosis irrespective of the age
at onset [49].
Treatment modalities remained basically unchanged
during the last decades and this is certainly one factor
influencing the still poor prognosis of acute episodes of
hyperammonemia. However, an even larger problem is the
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delay in start of appropriate treatment often due to lack of
awareness towards the rare differential diagnosis of an
inborn error of metabolism. Improved prognosis does
largely depend on shortening the time interval to diagnosis
[52] and this might even be more effective for the overall
cohort of patients than developing new treatment modalities
although these are much needed.
Chronic hyperammonemia
There are no firm data on the relevance of moderate chronic
hyperammonemia (which is a non-standard term used for
ammonia levels of up to 200 μmol/L). Likewise, there is no
safe upper level of ammonia concentration [4]. However, it
should be noted that “unexplained” moderate hyperammo-
nemia might be caused by excessive protein restriction or
caused by therapy with nitrogen scavengers itself. Data
from patients suffering from hepatic encephalopathy, an
adult disorder associated with chronic hyperammonemia,
point towards morphological changes of astrocytes, i.e.
development of so called Alzheimer type II astrocytes as
well as radical RNA damage and protein tyrosine nitration
[15, 16, 38]. Recent results of spectroscopy studies
performed in asymptomatic OTC carriers revealed changes
in astrocytic osmolyte balance caused by chronic elevations
of glutamine [30, 32]. Thus, there is cumulating evidence
for a pathological role of chronic moderate hyperammone-
mia but this area needs further studies. For the time being, it
appears to be advisable to strictly avoid any state of even
moderate, seemingly asymptomatic hyperammonemia in
order to avoid neurological damage.
Key points
➢ Good prognosis depends largely on shortening the time until start
of therapy
➢ Subclinical hyperammonemic episodes probably have an impact on
brain function
➢ Even moderate hyperammonemia should be avoided
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Additional note
The author is currently steering an international working group
(including Nathalie Boddaert, Paris; Alberto Burlina, Padua;
Anupam Chakrapani, Birmingham; Carlo Dionisi-Vici, Rome;
Marjorie Dixon, London; Martina Huemer, Bregenz; Daniela
Karall, Innsbruck; Martin Lindner, Heidelberg; Vicente Rubio,
Valencia; Aude Servais, Paris; Pablo Sanjurjo, Bilbao; René Santer,
Hamburg; Vassili Valayannopoulos, Paris) on “Guidelines for the
diagnosis and treatment of urea cycle disorders”. The author is
much obliged to all members of the working group who helped to
evaluate the literature and actively discussed many issues closely
related to hyperammonemia. The Guideline will be released to
many European National Metabolic Societies and as a publication
in 2011 and might provide additional information for the reader
interested in management of hyperammonemia.
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